Cost-Effectiveness and Budget Impact of a Novel Antithrombotic Drug Removal System to Reduce Bleeding Risk in Patients on Preoperative Ticagrelor Undergoing Cardiac Surgery
Benjamin G Cohen et al. Am J Cardiovasc Drugs. 2023.
Hide details
Am J Cardiovasc Drugs
. 2023 May 19.
doi: 10.1007/s40256-023-00587-4. Online ahead of print.
Authors
Benjamin G Cohen 1 , Francine Chingcuanco 2 , Jingwei Zhang 3 , Natalie M Reid 2 , Victoria Lee 3 , Jonathan Hong 4 , Efthymios N Deliargyris 3 , William V Padula 5 6 7
Affiliations
1 Stage Analytics, Duluth, GA, USA. benjamin.cohen@stageanalytics.com.
2 Stage Analytics, Duluth, GA, USA.
3 CytoSorbents Corporation, Princeton, NJ, USA.
4 St. Boniface Hospital, University of Manitoba, Winnipeg, MB, Canada.
5 Stage Analytics, Duluth, GA, USA. padula@usc.edu.
6 Department of Pharmaceutical and Health Economics, School of Pharmacy, University of Southern California, Los Angeles, CA, USA. padula@usc.edu.
7 The Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, USC Schaeffer Center, 635 Downey Way (VPD), Los Angeles, CA, 90089, USA. padula@usc.edu.
PMID: 37204675
DOI: 10.1007/s40256-023-00587-4
Cite
Abstract
Background: Antithrombotic drugs, including the P2Y12 inhibitor ticagrelor, increase the risk of perioperative bleeding in patients requiring urgent cardiac surgery. Perioperative bleeding can lead to increased mortality and prolong intensive care unit and hospital stays. A novel sorbent-filled hemoperfusion cartridge that intraoperatively removes ticagrelor via hemoadsorption can reduce the risk of perioperative bleeding. We estimated the cost-effectiveness and budget impact of using this device versus standard practices to reduce the risk of perioperative bleeding during and after coronary artery bypass grafting from the US healthcare sector perspective.
Methods: We used a Markov model to analyze the cost-effectiveness and budget impact of the hemoadsorption device in three cohorts: (1) surgery within 1 day from last ticagrelor dose; (2) surgery between 1 and 2 days from last ticagrelor dose; and (3) a combined cohort. The model analyzed costs and quality-adjusted life years (QALYs). Results were interpreted as both incremental cost-effectiveness ratios and net monetary benefits (NMBs) at a cost-effectiveness threshold of $100,000/QALY. We analyzed parameter uncertainty using deterministic and probabilistic sensitivity analyses.
Results: The hemoadsorption device was dominant for each cohort. Patients with less than 1 day of washout in the device arm gained 0.017 QALYs at a savings of $1748 (USD), for an NMB of $3434. In patients with 1-2 days of washout, the device arm yielded 0.014 QALYs and a cost savings of $151, for an NMB of $1575. In the combined cohort, device gained 0.016 QALYs and a savings of $950 for an NMB of $2505. Per-member-per-month cost savings associated with device was estimated to be $0.02 for a one-million-member health plan.
Conclusion: This model found the hemoadsorption device to provide better clinical and economic outcomes compared with the standard of care in patients who required surgery within 2 days of ticagrelor discontinuation. Given the increasing use of ticagrelor in patients with acute coronary syndrome, incorporating this novel device may represent an important part of any bundle to save costs and reduce harm.
